![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ARGFX |
Gene summary for ARGFX |
![]() |
Gene information | Species | Human | Gene symbol | ARGFX | Gene ID | 503582 |
Gene name | arginine-fifty homeobox | |
Gene Alias | ARGFX | |
Cytomap | 3q13.33 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | A6NJG6 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
503582 | ARGFX | HCC1 | Human | Liver | HCC | 2.91e-18 | 1.46e+00 | 0.5336 |
503582 | ARGFX | HCC2 | Human | Liver | HCC | 3.94e-24 | 1.37e+00 | 0.5341 |
503582 | ARGFX | HCC5 | Human | Liver | HCC | 1.99e-22 | 1.46e+00 | 0.4932 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ARGFX | SNV | Missense_Mutation | novel | c.384N>A | p.Asn128Lys | p.N128K | A6NJG6 | protein_coding | deleterious(0.02) | probably_damaging(0.998) | TCGA-CV-6945-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | PD |
ARGFX | SNV | Missense_Mutation | novel | c.860T>C | p.Met287Thr | p.M287T | A6NJG6 | protein_coding | tolerated(0.15) | benign(0) | TCGA-CV-A6JD-01 | Oral cavity | head & neck squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ARGFX | SNV | Missense_Mutation | c.591N>C | p.Glu197Asp | p.E197D | A6NJG6 | protein_coding | tolerated(0.47) | benign(0.007) | TCGA-P3-A5Q5-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
ARGFX | insertion | Frame_Shift_Ins | novel | c.284_285insAGATCCCAGG | p.Leu96AspfsTer6 | p.L96Dfs*6 | A6NJG6 | protein_coding | TCGA-CV-A45T-01 | Oral cavity | head & neck squamous cell carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
ARGFX | SNV | Missense_Mutation | rs149102809 | c.226N>T | p.Arg76Trp | p.R76W | A6NJG6 | protein_coding | tolerated(0.09) | benign(0) | TCGA-EJ-5524-01 | Prostate | prostate adenocarcinoma | Male | <65 | 9 | Unknown | Unknown | PD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |